New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

viatris limited - terazosin hydrochloride dihydrate 2.347mg equivalent to 2 mg terazosin - tablet - 2 mg - active: terazosin hydrochloride dihydrate 2.347mg equivalent to 2 mg terazosin excipient: lactose monohydrate magnesium stearate maize starch purified talc quinoline yellow starch - the symptomatic and pathophysiologic treatment of benign prostatic hyperplasia (bph) when: -prostatectomy is not indicated -patient is not fit for surgery -elective surgery must be postponed (e.g., waiting list) -patient refuses surgical treatment.

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

viatris limited - terazosin hydrochloride dihydrate 5.935mg equivalent to 5 mg terazosin - tablet - 5 mg - active: terazosin hydrochloride dihydrate 5.935mg equivalent to 5 mg terazosin excipient: iron oxide red lactose monohydrate magnesium stearate maize starch purified talc starch - the symptomatic and pathophysiologic treatment of benign prostatic hyperplasia (bph) when: -prostatectomy is not indicated -patient is not fit for surgery -elective surgery must be postponed (e.g., waiting list) -patient refuses surgical treatment.

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - terazosin hydrochloride anhydrous (unii: 8qop8z9955) (terazosin - unii:8l5014xet7) - terazosin 2 mg - terazosin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (bph). there is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of bph when treated with terazosin capsules. the long-term effects of terazosin capsules on the incidence of surgery, acute urinary obstruction or other complications of bph are yet to be determined. terazosin capsules are also indicated for the treatment of hypertension. it can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents. terazosin capsules are contraindicated in patients known to be hypersensitive to terazosin hydrochloride.

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

abbott laboratories (nz) ltd - terazosin hydrochloride dihydrate 11.87mg equivalent to 10 mg terazosin - tablet - 10 mg - active: terazosin hydrochloride dihydrate 11.87mg equivalent to 10 mg terazosin excipient: indigo carmine lactose monohydrate magnesium stearate maize starch purified talc

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

abbott laboratories (nz) ltd - terazosin hydrochloride dihydrate 1.187mg equivalent to 1 mg terazosin - tablet - 1 mg - active: terazosin hydrochloride dihydrate 1.187mg equivalent to 1 mg terazosin excipient: lactose monohydrate magnesium stearate maize starch purified talc

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

mylan institutional inc. - terazosin hydrochloride anhydrous (unii: 8qop8z9955) (terazosin - unii:8l5014xet7) - terazosin 1 mg - terazosin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (bph). there is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of bph when treated with terazosin capsules. the long-term effects of terazosin capsules on the incidence of surgery, acute urinary obstruction or other complications of bph are yet to be determined. terazosin capsules are also indicated for the treatment of hypertension. it can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents. terazosin capsules are contraindicated in patients known to be hypersensitive to terazosin hydrochloride.

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

state of florida doh central pharmacy - terazosin hydrochloride (unii: d32s14f082) (terazosin - unii:8l5014xet7) - terazosin hydrochloride 1 mg - terazosin hydrochloride is indicated for the treatment of symptomatic benign prostatic hyperplasia (bph). there is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of bph when treated with terazosin hydrochloride. the long-term effects of terazosin hydrochloride on the incidence of surgery, acute urinary obstruction or other complications of bph are yet to be determined. terazosin hydrochloride is also indicated for the treatment of hypertension. it can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents. terazosin hydrochloride capsules are contraindicated in patients known to be hypersensitive to terazosin hydrochloride.

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - terazosin hydrochloride anhydrous (unii: 8qop8z9955) (terazosin - unii:8l5014xet7) - terazosin 1 mg - terazosin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (bph). there is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of bph when treated with terazosin capsules. the long-term effects of terazosin capsules on the incidence of surgery, acute urinary obstruction or other complications of bph are yet to be determined. terazosin capsules are also indicated for the treatment of hypertension. it can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents. terazosin capsules are contraindicated in patients known to be hypersensitive to terazosin hydrochloride.

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

rebel distributors corp - terazosin hydrochloride (unii: d32s14f082) (terazosin - unii:8l5014xet7) - terazosin hydrochloride 2 mg - terazosin hydrochloride is indicated for the treatment of symptomatic benign prostatic hyperplasia (bph). there is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of bph when treated with terazosin hydrochloride. the long-term effects of terazosin hydrochloride on the incidence of surgery, acute urinary obstruction or other complications of bph are yet to be determined. terazosin hydrochloride is also indicated for the treatment of hypertension. it can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents. terazosin hydrochloride capsules are contraindicated in patients known to be hypersensitive to terazosin hydrochloride.

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

state of florida doh central pharmacy - terazosin hydrochloride (unii: d32s14f082) (terazosin - unii:8l5014xet7) - terazosin hydrochloride 1 mg - terazosin hydrochloride is indicated for the treatment of symptomatic benign prostatic hyperplasia (bph). there is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of bph when treated with terazosin hydrochloride. the long-term effects of terazosin hydrochloride on the incidence of surgery, acute urinary obstruction or other complications of bph are yet to be determined. terazosin hydrochloride is also indicated for the treatment of hypertension. it can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents. terazosin hydrochloride capsules are contraindicated in patients known to be hypersensitive to terazosin hydrochloride.